Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 8, 1998, Pages 797-805

  Martin, R M ^a,c   Lim, A G ^b   Kerry, S M ^a   Hilton, S R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ANTIULCER AGENT; PROTON PUMP;

ARTICLE; DYSPEPSIA; GASTRITIS; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; UNITED KINGDOM; DRUG ANTAGONISM; GASTROESOPHAGEAL REFLUX; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; STATISTICS; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GREAT BRITAIN; HISTAMINE H2 ANTAGONISTS; HUMANS; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0031596427     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00374.x     Document Type: Article

References (42)

1. Office of Health Economics. Drivers of Growth in Medicines Expenditure. London: OHE, 1997.
2. Audit Commission. A Prescription for Improvement: Towards more Rational Prescribing in General Practice. London: HMSO, 1994.
3. Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ. Long-term acid suppressing drugs in general practice. Br Med J 1994; 308: 827-30.
4. Moore R, Helicobater pylori and Peptic Ulcer. A Systematic Review of Effectiveness and an Overview of the Economic Benefits of Implementing what is Known to be Effective. Oxford: Health Technology Evaluation Association, 1994.
5. Majeed A, Evans N, Head P. What can PACT tell us about prescribing in general practice? Br Med J 1997; 315: 1515-19.
6. Hungin AP, Rubin GP, Russell AJ, Convery B. Guidelines for dyspepsia management in general practice using focus groups. Br J Gen Pract 1997; 47: 275-9.
7. Bosanquet N, Johnson N, Jones R. Developing Cost Effective Care. New Challenges in Acid-Peptic Disorders. Health policy review paper no. 9. London: St. Mary's Hospital Medical School, 1995.
8. Taylor R, Bond C. Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. Br J Gen Prac 1991; 41: 244-8.
9. Roberts S, Bateman D. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 137-43.
10. Rubin G, Contractor B, Bramble M. The use of long-term acid suppresson therapy. Br J Clin Pract 1995; 49: 119-20.
11. Norris C, McManus P, Petty D, Kay E. A drug usage review of omeprazole. J Clin Pharmacy Ther 1992; 17: 369-72.
12. Armstrong D, Reyburn H, Jones R. A study of general practitioners' reasons for changing their prescribing behaviour. Br Med J 1996; 312: 949-52.
13. Martin R, Hilton S, Kerry S, Richards N. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Br Med J 1997; 314: 646-51.
14. Martin R, Hilton S, Kerry S. Review of prescribed treatment for children with asthma. Br Med J 1995; 311: 1645.
15. Department of Health. Health and Personal Social Services Statistics for England. London: HMSO, 1995.
16. Office of Population Censuses and Surveys, Department of Health. Population Trends no. 83. London: HMSO, 1996.
17. Joint Formulary Committee. British National Formulary no. 32. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1996: 28-41.
18. Drug Intelligence Group North Thames Region. Survey of Ulcer Healing Drugs in Hospitals and FHSAs 1990-94. London: Drug Intelligence Group North Thames Region, 1994.
19. Mackay F, Stephens M, Freemantle S, Pearce G, Wilton L, Mann RD. Lansoprazole, PEM Report no. 33. Southampton: Drug Safety Research Unit, 1997.
20. Goudie B, McKenzie P, Cipriano J, Griffin E, Murray F. Repeat prescribing of ulcer healing drugs in general practice - prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 147-90.
21. Bodger K, Daly M, Heatley R. Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners. Aliment Pharmacol Ther 1996; 10: 889-95.
22. Armstrong D, Calnan M, Grace J. Reliability and validity. In: Research Methods for General Practitioners. New York: Oxford University Press, 1990: 46-8.
23. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med J 1989; 290: 30-2.
24. Quine MA, Bell GD, McCloy RF, Charlton JE, Devlin HB, Hopkins A. A prospective audit of upper gastrointestinal endoscopy in two regions of England. Gut 1995; 310: 853-6.
25. Jones RH, Lydeard SE, Hobbs FDR, Kenkre JE, Williams EI, Jones SJ, et al. Dyspepsia in England and Scotland, Gut 1990; 31: 401-5.
26. Nebel O, Fornes M, Castell D. Symptomatic gastro-oesophageal reflux disease: incidence and precipictating factors. Dig Dis 1976; 21: 953-6.
27. Anon. Nature and standards of gastrointestinal and liver services in the UK. A special report of the British Society of Gastroenterology, Gut 1993; 34: 1728-39.
28. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283-8.
29. Royal College of General Practitioners, Office of Population and Censuses and Surveys. Department of Health and Social Security. Mobidity statistics from general practice. London: HMSO, 1985.
30. McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice. Fourth national study 1991-92. Royal College of General Practitioners. Office of Population and Censuses and Surveys, Department of Health. London: HMSO, 1995.
31. Boath E, Blenkinsopp A. The rise of proton pump inhibitors: patient demand or profligate prescribing? Drug Utilisation Research Group Annual Scientific Meeting. London: Royal Society of Medicine, 1996.
32. Anon. Lansoprazole - another proton pump inhibitor. Drug Ther Bull 1995; 33: 36-7.
33. Blum R. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm 1996; 53: 1401-15.
34. McGavock H, Webb C, Johnston G, Milligan E. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators. Br Med J 1993; 307: 1118-20.
35. Talley N, Weaver A, Tesmer D, Zinsmeister A. Lack of discriminat value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-86.
36. Brown C, Rees WDW. Dyspepsia in general practice. Br Med J 1990; 300: 829-30.
37. 2-blocker therapy or prompt endoscopy in managemnt of dyspepsia. Lancet 1994; 343: 811-16.
38. Talley N, Colin-Jones D, Koch K, Nyren O, Stranghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
39. Hungin A, Thomas P, Bramble M, et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994; 44: 519-21.
40. Patel P, Khulusi S, Mendall MA, Lloyd R, Maxwell JD, Northfield TC. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995; 546: 1515-18.
41. Lim AG, Martin RM, Montileone M, Walker AC, Gould SR. Helicobacter pylori and the management of young dyspeptics: a survey of gastroenterologists and general practitioners with an interest in gastroenterology. Aliment Pharmacol Ther 1997; 11: 299-303.
42. Prach AT, McGilchrist MM, White G, McDevitt DG, MacDonald TM, Murray FE. The pattern of prescribing of community-dispensed ulcer-healing drugs in Tayside. Scotland. 1989-92. Pharmacoepidemiol Drug Safety 1996; 5: S35.